Charted in the Dark: Inside the Counterfeit Dosing Guides Circulating Through Encrypted Pet-Drug Channels

A Dosing Chart No Veterinarian Wrote

The documents circulate with professional polish: species-by-species tables, milligram-per-kilogram conversions, even withdrawal intervals rendered in a clean sans-serif typeface. They recommend 'sub-threshold' doses of psilocybin, ketamine analogs, and 5-MeO-DMT for dogs, cats, and — in one widely forwarded chart — parrots. None of them carry an author, a license number, or a citation. That absence is the point.

These fabricated guides, marketed as 'vet dose' references, have become a fixture of encrypted channels and gray-market storefronts where psychoactive compounds are sold alongside supplements and nootropics. Their visual authority does real work: it converts an illicit purchase into something that feels like a clinical decision.

Why the Fakes Spread

The psychology is straightforward. Pet owners confronting anxiety, seizures, or end-of-life decline in their animals often meet the same walls human patients faced a decade ago — long waitlists, limited options, and a wellness culture eager to fill the gap. A laminated-looking dosing table, forwarded through a Telegram group with thousands of members, supplies the one thing an underground vendor cannot otherwise offer: the appearance of legitimacy.

The problem is that the numbers are frequently invented. Toxicologists consulting on companion-animal psychedelic exposures report that published pharmacokinetic data for these compounds in dogs and cats is thin to nonexistent. Any chart promising precise feline dosing of a Schedule I tryptamine is extrapolating from — at best — rodent studies, or at worst, nothing at all.

The Regulatory Whack-a-Mole

Enforcement architecture in the United States was simply not built for this. The FDA regulates labeling of animal drugs; state boards of pharmacy license the dispensing of them; state veterinary medical boards discipline practitioners. An anonymous vendor on an encrypted app, selling an unapproved compound with a fabricated dosing guide, slips between all three.

Several dynamics compound the gap:

• Labeling jurisdiction ends at approval. Unapproved compounds aren't subject to animal drug labeling rules, so a fraudulent chart isn't 'mislabeling' in the statutory sense — it's just paper.
• Telehealth loopholes travel. Platforms offering remote 'veterinary wellness consultations' operate across state lines, and disciplinary authority stops at each board's border.
• Platform moderation is reactive. Encrypted services resist content takedowns by design, and marketplace operators routinely relist under new storefront names after removal.

State pharmacy boards have begun issuing consumer advisories, and the AVMA has published guidance warning members about owner-initiated psychedelic dosing. But advisories move at the speed of committees; charts move at the speed of a forwarded message.

What Lands in the Hospital

The clinical picture is what one might expect when fiction masquerades as pharmacology. Emergency clinicians describe presentations that mirror the diagnostic traps already familiar to this beat: ataxia, mydriasis, and agitation in a dog whose owner brought along a printed chart — and no packaging, no concentration data, no idea what analog was actually in the vial. The mass spectrometry void documented elsewhere on this site becomes acute here, because the counterfeit charts frequently reference compounds whose identities don't match what's in the product.

Worse, some charts advise against veterinary consultation, framing clinicians as ignorant of 'therapeutic dosing' or fearful of legal exposure. This is a deliberate trust inversion: the fabricated document positions itself as the insider knowledge and the licensed professional as the obstacle.

Closing the Gap

Meaningful response likely requires three moves. First, labeling law needs a category for fraudulent clinical documentation — not just fraudulent products — so that fabricated dosing guides fall within existing enforcement tools. Second, state veterinary boards need clear safe-harbor language confirming that clinicians who treat psychedelic exposures face no professional jeopardy, removing the leverage the counterfeit charts exploit. Third, veterinary curricula — several of which are already building psychedelic literacy — should include exposure recognition so the first clinician to see these cases knows what they're looking at.

The counterfeit chart is a document problem wearing a pharmacology costume. Until regulators treat it as such, the most dangerous thing moving through these channels won't be the compounds. It will be the paper that tells owners they're safe to use them.